In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections

S McCurdy, L Lawrence, M Quintas, L Woosley, R Flamm, C Tseng, S Cammarata, S McCurdy, L Lawrence, M Quintas, L Woosley, R Flamm, C Tseng, S Cammarata

Abstract

Delafloxacin is an investigational anionic fluoroquinolone antibiotic with broad-spectrum in vitro activity, including activity against Gram-positive organisms, Gram-negative organisms, atypical organisms, and anaerobes. The in vitro activity of delafloxacin and the percent microbiological response in subjects infected with fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates were determined from two global phase 3 studies of delafloxacin versus vancomycin plus aztreonam in patients with acute bacterial skin and skin structure infections (ABSSSI). Patients from 23 countries, predominately the United States but also Europe, South America, and Asia, were enrolled. The microbiological intent-to-treat (MITT) population included 1,042 patients from which 685 S. aureus isolates were submitted for identification and susceptibility testing per CLSI guidelines at the central laboratory (JMI Laboratories, North Liberty, IA). The comparator fluoroquinolone antibiotics included levofloxacin and ciprofloxacin. Nonsusceptibility to these antibiotics was determined using CLSI breakpoints. S. aureus isolates were 33.7% levofloxacin nonsusceptible (LVX-NS). The delafloxacin MIC90 values against levofloxacin-nonsusceptible S. aureus, methicillin-resistant S. aureus (MRSA), and methicillin-susceptible S. aureus isolates were all 0.25 μg/ml. Delafloxacin demonstrated high rates of microbiological response against LVX-NS isolates as well as isolates with documented mutations in the quinolone resistance-determining region (QRDR). S. aureus was eradicated or presumed eradicated in 98.4% (245/249) of delafloxacin-treated patients. Similar eradication rates were observed for delafloxacin-treated subjects with levofloxacin-nonsusceptible S. aureus isolates (80/81; 98.8%) and MRSA isolates (70/71; 98.6%). Microbiological response rates of 98.6% were observed with delafloxacin-treated subjects with S. aureus isolates with the S84L mutation in gyrA and the S80Y mutation in parC, the most commonly observed mutations in global phase 3 studies. The data suggest that delafloxacin could be a good option for the treatment of infections caused by S. aureus isolates causing ABSSSI, including MRSA isolates, where high rates of ciprofloxacin and levofloxacin nonsusceptibility are observed. (The phase 3 studies described in this paper have been registered at ClinicalTrials.gov under identifiers NCT01984684 and NCT01811732.).

Keywords: ABSSSI; Staphylococcus aureus; delafloxacin; fluoroquinolone; susceptibility.

Copyright © 2017 McCurdy et al.

References

    1. Garau J. 2006. Management of cSSTIs: the role of daptomycin. Curr Med Res Opin 22:2079–2087. doi:10.1185/030079906X148292.
    1. Caínzos M. 2008. Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections—are they applicable today? Clin Microbiol Infect 14(Suppl 6):9–18. doi:10.1111/j.1469-0691.2008.02123.x.
    1. Ray GT, Suaya JA, Baxter R. 2013. Microbiology of skin and soft tissue infections in the age of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 76:24–30. doi:10.1016/j.diagmicrobio.2013.02.020.
    1. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. 2014. Practice guidelines for the diagnosis and management of skin and soft-tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 59:147–159. doi:10.1093/cid/ciu444.
    1. Dryden MS. 2009. Skin and soft tissue infection: microbiology and epidemiology. Int J Antimicrob Agents 34(Suppl 1):S2–S7. doi:10.1016/S0924-8579(09)70541-2.
    1. Dryden MS. 2010. Complicated skin and soft tissue infection. J Antimicrob Chemother 65(Suppl 3):iii35–iii44. doi:10.1093/jac/dkq302.
    1. Pfaller MA, Sader HS, Rhomberg PR, Flamm RK. 2017. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother 61:e02609-16. doi:10.1128/AAC.02609-16.
    1. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. 2003. In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob Agents Chemother 47:3008–3011. doi:10.1128/AAC.47.9.3008-3011.2003.
    1. Hammerschlag MR, Roblin PM. 2004. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae. J Antimicrob Chemother 54:281–282.
    1. Waites KB, Crabb DM, Duffy LB. 2003. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 47:3973–3975. doi:10.1128/AAC.47.12.3973-3975.2003.
    1. Van Bambeke F. 2015. Delafloxacin, a non-zwitterionic fluoroquinolone in phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol 10:1111–1123. doi:10.2217/fmb.15.39.
    1. Nilius AM, Shen LL, Hensey-Rudloff D, Almer LS, Beyer JM, Balli DJ, Cai Y, Flamm RK. 2003. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother 47:3260–3269. doi:10.1128/AAC.47.10.3260-3269.2003.
    1. Remy JM, Tow-Keogh CA, McConnell TS, Dalton JM, Devito JA. 2012. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother 67:2814–2820. doi:10.1093/jac/dks307.
    1. Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. 2015. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13). J Antimicrob Chemother 70:498–504. doi:10.1093/jac/dku421.
    1. Bensaci M, Sahm D. 2017. Surveillance of tedizolid activity and resistance: in vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe. Diagn Microbiol Infect Dis 87:133–138. doi:10.1016/j.diagmicrobio.2016.10.009.
    1. Ehlers C, Ivens UI, Møller ML, Senderovitz T, Serup J. 2001. Females have lower skin surface pH than men. A study on the surface of gender, forearm site variation, right/left difference and time of the day on the skin surface pH. Skin Res Technol 7:90–94.
    1. Bessman AN, Page J, Thomas LJ. 1989. In vivo pH of induced soft-tissue abscesses in diabetic and nondiabetic mice. Diabetes 38:659–662.
    1. U.S. Food and Drug Administration. 2013. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. U.S. Food and Drug Administration, Rockville, MD: .
    1. European Medicines Agency. 2013. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Committee for Human Medicinal Products, European Medicines Agency, London, United Kingdom: .
    1. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 10th ed CLSI document M07-A10 Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; twenty-sixth informational supplement. CLSI document M100-S26 Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Toshinobu H, Yasuhiro S, Akio M, Motoki M, Hideaki M, Yoko K, Matsuko D, Akihiro T, Takashi K, Masato M. 2003. Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs. Diagn Microbiol Infect Dis 46:139–145. doi:10.1016/S0732-8893(03)00037-3.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren